NAVB - Navidea Biopharmaceuticals, Inc
| Previous Close | 0.4165 |
| Open | 0.4200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.4050 - 0.4200 |
| 52 Week Range | 0.2900 - 1.1600 |
| Volume | 196,932 |
| Avg. Volume | 243,864 |
| Market Cap | 67.41M |
| Beta | -1.25 |
| PE Ratio (TTM) | 0.86 |
| EPS (TTM) | 0.48 |
| Earnings Date | Mar 24, 2017 - Mar 27, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.25 |
- Capital Cube•11 days ago
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : October 10, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Navidea Biopharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NAVB-US. Comparing the performance and risk of Navidea Biopharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Capital Cube•23 days ago
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : September 28, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Navidea Biopharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NAVB-US. Comparing the performance and risk of Navidea Biopharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Capital Cube•24 days agoNavidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017
Categories: Yahoo FinanceGet free summary analysis Navidea Biopharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Navidea Biopharmaceuticals, Inc. – Immunomedics, Inc., AMAG Pharmaceuticals, Inc., Cardinal Health, Inc., International Isotopes Inc., Fonar Corporation, iCAD, Inc. and Austal Limited Sponsored ADR (IMMU-US, AMAG-US, CAH-US, INIS-US, ... Read more (Read more...)
- Business Wire•last month
Navidea Biopharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Navidea Biopharmaceuticals, Inc. , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the Rodman & Renshaw 19th Annual Global Investment Conference, being held September 10-12, 2017, in New York, NY.
- Business Wire•2 months ago
Navidea To Initiate Regular Webcast Series Featuring Moderated Q&A with Management
Navidea Biopharmaceuticals , a company focused on the development of precision immunodiagnostic agents and through its subsidiary Macrophage Therapeutics, immunotherapeutics, announced today that it will hold an Investor Relations -focused, online Question & Answer Session with Jed Latkin, Chief Financial and Chief Operating Officer of Navidea on Tuesday, September 5 at 4:30pm Eastern Time.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of NAVB earnings conference call or presentation 9-Aug-17 12:00pm GMT
Q2 2017 Navidea Biopharmaceuticals Inc Earnings Call
- Associated Press•2 months ago
Navidea reports 2Q loss
On a per-share basis, the Dublin, Ohio-based company said it had a loss of 3 cents. Losses, adjusted to account for discontinued operations, were 2 cents per share. The biopharmaceutical posted revenue ...
- ACCESSWIRE•2 months ago
Investor Network: Navidea Biopharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2017 / Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB ) will be discussing their earnings results in their Q2 Earnings Call to be held August 9, 2017 at 8:00 ...
- Business Wire•2 months ago
Navidea Biopharmaceuticals Reports Second Quarter 2017 Financial Results
Navidea Biopharmaceuticals, Inc. , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter of 2017.
- Business Wire•4 months ago
Navidea Enters Exclusive License and Distribution Agreement For India with Sayre Therapeutics
Navidea Biopharmaceuticals, Inc. , a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that it has entered into an exclusive license and distribution agreement with Sayre Therapeutics for the development and commercialization of Tc 99m tilmanocept in India.
- Business Wire•4 months ago
Navidea’s Commercial Partner, Norgine B.V., Launches LYMPHOSEEK® in Europe
Navidea Biopharmaceuticals, Inc. , a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that its European commercial partner, SpePharm AG, an affiliate of Norgine, B.V., launched LYMPHOSEEK® , originally developed by Navidea, in Denmark, the Netherlands and the UK.
- Capital Cube•4 months ago
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : June 9, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Navidea Biopharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NAVB-US. Comparing the performance and risk of Navidea Biopharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Business Wire•5 months ago
Navidea Biopharmaceuticals to Present at the 7th Annual LD Micro Invitational Investor Conference
Navidea Biopharmaceuticals, Inc. , a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the 7th Annual LD Micro Invitational investor conference being held June 6-7, 2017 in Los Angeles, CA.
Capital Cube•5 months agoNavidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017
Categories: Yahoo FinanceGet free summary analysis Navidea Biopharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Navidea Biopharmaceuticals, Inc. – Immunomedics, Inc., AMAG Pharmaceuticals, Inc., Eli Lilly and Company, General Electric Company, Cardinal Health, Inc., International Isotopes Inc., Fonar Corporation and iCAD, Inc. (IMMU-US, ... Read more (Read more...)
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of NAVB earnings conference call or presentation 10-May-17 12:00pm GMT
Q1 2017 Navidea Biopharmaceuticals Inc Earnings Call
- Associated Press•5 months ago
Navidea posts 1Q profit
The Dublin, Ohio-based company said it had profit of 52 cents per share. Losses, adjusted to account for discontinued operations, came to 1 cent per share. The biopharmaceutical posted revenue of $580,000 ...
- Business Wire•5 months ago
Navidea Biopharmaceuticals Reports First Quarter 2017 Financial Results
Navidea Biopharmaceuticals, Inc. , a company focused on the development and commercialization of precision immunodiagnostic agents, today announced its financial results for the first quarter of 2017.
- Business Wire•6 months ago
Navidea Biopharmaceuticals Invited to Present Data at Two Major Upcoming Conferences
Navidea Biopharmaceuticals, Inc. , a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that it has been invited to present data at two major upcoming conferences.
- Capital Cube•6 months ago
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : April 19, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Navidea Biopharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NAVB-US. Comparing the performance and risk of Navidea Biopharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)